drugset / Trial / NCT01807741
Asenapine for Bipolar Depression
Phase 2
Terminated
51 enrolled
University of Cincinnati
Merck Sharp & Dohme LLC · collabUniversity of Louisville · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare asenapine with placebo in the treatment of depression associated with bipolar disorder, type I over eight weeks. We hypothesize that patients will show significantly greater improvement with asenapine than placebo over eight weeks of treatment.
Timeline
- Start
- 2013-09
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asenapine | Other / unclassified | 5 mg | Other |
| Subject | Asenapine | Other / unclassified | 10 mg | Other |